New drug under watch for Prader-Willi syndrome
Disease control
ENROLLING_BY_INVITATION
This study follows about 200 people with Prader-Willi syndrome who are taking or starting VYKAT XR. Researchers want to see how safe the drug is and how patients do over time. The goal is to learn more, not to test if the drug works as a cure.
Sponsor: Soleno Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC